Rebound hyperkalemia after cessation of intravenous tocolytic therapy with terbutaline in the treatment of preterm labor: anesthetic implications.
Beta-adrenergic agents have been widely used in obstetrics to attenuate premature labor (termed tocolytic therapy), delay delivery, allow fetal maturation, and thereby reduce neonatal morbidity and mortality. Hypokalemia is a common side effect during beta-adrenergic tocolytic therapy for the treatment of preterm labor. Although rebound hyperkalemia after cessation of tocolytic therapy with ritodrine has been reported, there have been no reports of hyperkalemia occurring after the cessation of beta-adrenergic tocolytic therapy with terbutaline for preterm labor; we report such a case.
D000328:Adult; D000773:Anesthesia, Obstetrical; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000503:physiopathology; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007262:Infusions, Intravenous; D007752:Obstetric Labor, Premature / Q000097:blood* / Q000188:drug therapy*; D011247:Pregnancy; D013726:Terbutaline / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015145:Tocolysis; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D015149:Tocolytic Agents; D013726:Terbutaline